148 related articles for article (PubMed ID: 32473178)
41. Immune Checkpoint Blockade in Breast Cancer Therapy.
Bu X; Yao Y; Li X
Adv Exp Med Biol; 2017; 1026():383-402. PubMed ID: 29282694
[TBL] [Abstract][Full Text] [Related]
42. Mutations Associated with No Durable Clinical Benefit to Immune Checkpoint Blockade in Non-S-Cell Lung Cancer.
Zhu G; Ren D; Lei X; Shi R; Zhu S; Zhou N; Zu L; Mello RA; Chen J; Xu S
Cancers (Basel); 2021 Mar; 13(6):. PubMed ID: 33808631
[TBL] [Abstract][Full Text] [Related]
43. Finding the hot spot: identifying immune sensitive gastrointestinal tumors.
De Souza ALPB
Transl Gastroenterol Hepatol; 2020; 5():48. PubMed ID: 33073043
[TBL] [Abstract][Full Text] [Related]
44. Elimination of tumor by CD47/PD-L1 dual-targeting fusion protein that engages innate and adaptive immune responses.
Liu B; Guo H; Xu J; Qin T; Guo Q; Gu N; Zhang D; Qian W; Dai J; Hou S; Wang H; Guo Y
MAbs; 2018; 10(2):315-324. PubMed ID: 29182441
[TBL] [Abstract][Full Text] [Related]
45. Selective SIRPα blockade reverses tumor T cell exclusion and overcomes cancer immunotherapy resistance.
Gauttier V; Pengam S; Durand J; Biteau K; Mary C; Morello A; Néel M; Porto G; Teppaz G; Thepenier V; Danger R; Vince N; Wilhelm E; Girault I; Abes R; Ruiz C; Trilleaud C; Ralph K; Trombetta ES; Garcia A; Vignard V; Martinet B; Glémain A; Bruneau S; Haspot F; Dehmani S; Duplouye P; Miyasaka M; Labarrière N; Laplaud D; Le Bas-Bernardet S; Blanquart C; Catros V; Gouraud PA; Archambeaud I; Aublé H; Metairie S; Mosnier JF; Costantini D; Blancho G; Conchon S; Vanhove B; Poirier N
J Clin Invest; 2020 Nov; 130(11):6109-6123. PubMed ID: 33074246
[TBL] [Abstract][Full Text] [Related]
46. Blockade of myeloid-derived suppressor cell function by valproic acid enhanced anti-PD-L1 tumor immunotherapy.
Adeshakin AO; Yan D; Zhang M; Wang L; Adeshakin FO; Liu W; Wan X
Biochem Biophys Res Commun; 2020 Feb; 522(3):604-611. PubMed ID: 31785814
[TBL] [Abstract][Full Text] [Related]
47. Therapy With Carboplatin and Anti-PD-1 Antibodies Before Surgery Demonstrates Sustainable Anti-Tumor Effects for Secondary Cancers in Mice With Triple-Negative Breast Cancer.
Gao M; Wang T; Ji L; Bai S; Tian L; Song H
Front Immunol; 2020; 11():366. PubMed ID: 32194569
[TBL] [Abstract][Full Text] [Related]
48. Harnessing the bioresponsive adhesion of immuno-bioglue for enhanced local immune checkpoint blockade therapy.
Joo KI; Jeong Y; Hwang SM; Shin M; Lee J; Sharma G; Lee H; Im SH; Cha HJ
Biomaterials; 2020 Dec; 263():120380. PubMed ID: 32942128
[TBL] [Abstract][Full Text] [Related]
49. Neoadjuvant Interferons: Critical for Effective PD-1-Based Immunotherapy in TNBC.
Brockwell NK; Owen KL; Zanker D; Spurling A; Rautela J; Duivenvoorden HM; Baschuk N; Caramia F; Loi S; Darcy PK; Lim E; Parker BS
Cancer Immunol Res; 2017 Oct; 5(10):871-884. PubMed ID: 28848054
[TBL] [Abstract][Full Text] [Related]
50. Targeting immune pathways in breast cancer: review of the prognostic utility of TILs in early stage triple negative breast cancer (TNBC).
Blackley EF; Loi S
Breast; 2019 Nov; 48 Suppl 1():S44-S48. PubMed ID: 31839159
[TBL] [Abstract][Full Text] [Related]
51. T-cell programming in pancreatic adenocarcinoma: a review.
Seo YD; Pillarisetty VG
Cancer Gene Ther; 2017 Mar; 24(3):106-113. PubMed ID: 27910859
[TBL] [Abstract][Full Text] [Related]
52. On-demand integrated nano-engager converting cold tumors to hot
Liu X; Liang S; Sang X; Chang L; Fu S; Yang H; Yang H; Liu Y; Zhang N
Acta Pharm Sin B; 2023 Apr; 13(4):1740-1754. PubMed ID: 37139406
[TBL] [Abstract][Full Text] [Related]
53. Rationally combining immunotherapies to improve efficacy of immune checkpoint blockade in solid tumors.
Dammeijer F; Lau SP; van Eijck CHJ; van der Burg SH; Aerts JGJV
Cytokine Growth Factor Rev; 2017 Aug; 36():5-15. PubMed ID: 28693973
[TBL] [Abstract][Full Text] [Related]
54. Berberine diminishes cancer cell PD-L1 expression and facilitates antitumor immunity
Liu Y; Liu X; Zhang N; Yin M; Dong J; Zeng Q; Mao G; Song D; Liu L; Deng H
Acta Pharm Sin B; 2020 Dec; 10(12):2299-2312. PubMed ID: 33354502
[TBL] [Abstract][Full Text] [Related]
55. Optimizing poly (ADP-ribose) polymerase inhibition through combined epigenetic and immunotherapy.
Prasanna T; Wu F; Khanna KK; Yip D; Malik L; Dahlstrom JE; Rao S
Cancer Sci; 2018 Nov; 109(11):3383-3392. PubMed ID: 30230653
[TBL] [Abstract][Full Text] [Related]
56. Macrophage-Derived CXCL9 and CXCL10 Are Required for Antitumor Immune Responses Following Immune Checkpoint Blockade.
House IG; Savas P; Lai J; Chen AXY; Oliver AJ; Teo ZL; Todd KL; Henderson MA; Giuffrida L; Petley EV; Sek K; Mardiana S; Gide TN; Quek C; Scolyer RA; Long GV; Wilmott JS; Loi S; Darcy PK; Beavis PA
Clin Cancer Res; 2020 Jan; 26(2):487-504. PubMed ID: 31636098
[TBL] [Abstract][Full Text] [Related]
57. Opportunities for Antigen Discovery in Metastatic Breast Cancer.
Sood AK; Nemeth M; Wang J; Wu Y; Gandhi S
Front Immunol; 2020; 11():570049. PubMed ID: 33193348
[TBL] [Abstract][Full Text] [Related]
58. Targeting immune-checkpoint inhibitor resistance mechanisms by MEK inhibitor and agonist anti-CD40 antibody combination therapy.
Baumann D; Offringa R
Cell Stress; 2020 Aug; 4(10):248-251. PubMed ID: 33024933
[TBL] [Abstract][Full Text] [Related]
59. Recent Advances in Stimuli-Responsive Platforms for Cancer Immunotherapy.
Li L; Yang Z; Chen X
Acc Chem Res; 2020 Oct; 53(10):2044-2054. PubMed ID: 32877161
[TBL] [Abstract][Full Text] [Related]
60. Cancer immunotherapy targeting the CD47/SIRPα axis.
Weiskopf K
Eur J Cancer; 2017 May; 76():100-109. PubMed ID: 28286286
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
